feedback launch obsv
ftsv
overal investor sentiment toward name skew posit though
dialogu certainli reveal bull bear name
highest interest name among recent
bull highlight small cap biotech compani
could possibl see massiv appreci next year
establish poc efficaci asthma becom de-risk across
multipl indic program get investor radar
bear argu manag set expect asthma
readout may put competit play field
sny/regn dupix question whether limit dataset atop
dermat asthma enough drive valuat substanti higher
frequent question weve receiv along thought
bar asthma readout term
think manag guidanc improv vs
placebo reason go-forward criteria asthma readout
especi consid single-dos natur studi think peak
improv like creep percent long-term
exposur consist dupi activ agent result
estim better peak improv initi
updat adequ support poc drug correspond higher
po asthma lead higher valuat less
confid stock could respond result bottom end
rang would argu would continu see
develop warrant base kol convers
realli matter compani show improv instead
fundament dont see much differ
improv dont expect kol respons data differ
either scenario critic think proven
demonstr clinic competit result control set
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
asthma studi enough establish proof concept
comfort posit durabl clinic find
reward investor concern small sampl size amplifi
risk fals positive/fals neg result owe variabl around
improv endpoint placebo activ arm
overal think fact trial placebo-control significantli
strengthen interpret make extrapol indic
credibl strong result
what read-through studi reduct exacerb
expect endpoint expect statist
signific result studi
highlight genet link asthma well
reduct blood eosinophil seen atop dermat
posit indic approach yield posit lt result
manag asthma note improv blood
eosinophil level direct indic efficaci see
clear magnitud effect correl endpoint
exacerb reduct base review multipl biolog studi
indic
given small sampl size variabl seen asthma studi
dont believ studi adequ power stat-sig endpoint
much could stock move best case/worst case outcom
previous describ tp increas posit
outcom asthma justifi increas po asthma
argu result top rang could
ad halo effect increas po atop dermat even
broadli across pipelin potenti support tp
increas see downsid risk tp
failur achiev rang asthma think ad
lost valu indic pipelin could result
short-term though could rapidli recov asthma
setback posit initi read gpp program later
feedback investor larg posit signific
pushback bullish risdiplam sma thesi overal felt like
investor hadnt focus stori recent mani
recent convers consist bring investor speed
name agre view risdiplam could long-term valu
driver limit downsid event failur investor
offer push-back peak sma assumpt valu
royalti stream go estim dmd commerci franchis
support floor valuat final sever
question thought around agili acquisit last week
key question answer
thought agili acquisit
outlin note gene therapi space agili
acquisit fit compani rare diseas focu add gene
therapi capabl augment nonsens read-through splice
expertis think timelin laid compani aadc
program repres best-cas scenario lean toward
conserv outlook file timelin pend manag hold
direct convers fda
gene therapi platform may long-term growth driver
believ stock perform next year driven risdiplam
develop especi initi data type sma patient
potenti around world muscl societi meet data
type sma potenti
could risdiplam worth greater
valu gene therapi
believ gene therapi sma may potent
product risdiplam make case risdiplam may hold
greater commerci valu see ultim treat
newborn diagnos sma newborn screen younger type
patient expect risdiplam fill sever market nich support
peak sale assumpt add-on incomplet respond gene
therapi convers spinraza patient treatment older type
patient gene therapi may less attract option spinraza
adopt due spinal fusion complic less sever
model suggest potenti risdiplam achiev annual
sale peak receiv royalti level see
potenti upsid current target price tp would
approach rang event full de-risk risdiplam
receiv limit pushback thesi inbound
mostli investor invest name discuss
focus mostli expect time potenti clinic updat
competitor sourc potenti differenti among differ
target approach bull focu multi-billion dollar potenti
class highlight ftsv leadership posit field investor
cautiou name question class potenti
highlight competit space
meaning clinic catalyst next month
what best time get name
dont expect meaning clinic updat ftsv
remaind might see data competitor
decemb potenti venu updat oncolog
compani present preliminari phase result addit
system intra-tumor deliveri trillium perhap
earli updat celgen on-going studi aml solid
tumor nhl combin rituximab depend data
think ftsv current valuat posit result potenti
updat like valid class creat
substanti competit doubt see ftsv valuat attract
nhl alon expect option addit indic
slowli build stock next month even absenc
catalyst ahead data
enough upsid class
believ overexpress report multipl type
cancer strong scientif rational combin use
across indic earli efficaci r/r solid tumor colorect
ovarian believ derisk may open
opportun two indic alon promis efficaci nhl
could warrant explor earlier line treatment could
expand address market roughli larger
line accord expert believ blue-ski scenario
class though take time play
investor debat focus size endometriosi market
abil support market particip bull focu obsv valuat
rel peer highlight linzagolix may abl differenti
oral gnrh receptor antagonist allow captur healthi
market share within possibl endometriosi market
meanwhil bear cautiou market opportun
question regard obsv would compet larger market
stock under-valued rel peer share
declin orilissa abbv/nbix approv
think obsv under-valued compar peer base market
capit linzagolix year behind orilissa
behind relugolix treatment endometriosi expert believ
could overcom third-to-market posit convey stronger efficaci
orilissa low-dos without need estrogen add-back therapi
bone miner densiti data expect clarifi
possibl key catalyst program
arent sure linkag orilissa approv obseva
share pull back highlight time market gap
therapi orilissa label allow physician usag
qd dose regimen without though think obsv linzagolix
deliv better profil qd orilissa qd
compani mention price
martin auster certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
price rate histori inc anab oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori forti seven inc ftsv oq
signifi initi assumpt coverag
charl martineau pm univers toronto price rate histori obseva sa obsv oq
signifi initi assumpt coverag
price rate histori oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun octob canadian well european rate base stock total
return rel analyst coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun latin american asia stock exclud japan
australia rate base stock total return rel averag total return relev countri region benchmark india bse sensex
prior octob canadian rate base stock absolut total return potenti current share price rel
attract stock total return potenti within analyst coverag univers australian new zealand stock expect total return
calcul includ roll dividend yield outperform rate assign greater equal under-perform
less equal neutral may assign overlap rate rang allow analyst assign rate
put context associ risk prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate invest
view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least past
month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
bank client
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform close
